reports
Dentsply Sirona to Present at the 43rd Annual J.P. Morgan Healthcare C...
Dentsply Sirona to Present at the 43rd Annual J.P. Morgan Healthcare Conference CHARLOTTE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Wednesday, January 15, 2025, at 7:30 am PT (10:30 am ET). Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at About Dentsp...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Growth Leading This EOY Rally; Expect More Upside Our outlook remains bullish and we see the market in the midst of a significant end-of-year rally that we have been expecting since mid-October. We continue to expect support at the 20-day MAs on the S&P 500 and Nasdaq 100 (QQQ), while support at current levels or the 50-day MA is likely on the Russell 2000 (IWM). Ultimately, we will remain bullish as long as the S&P 500 is above 5850. Market dynamics continue to improve, giving us confidence th...
VIAV VIAVI SOLUTIONS INC
MEI METHODE ELECTRONICS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
INFN INFINERA CORPORATION
GLW CORNING INC
EXTR EXTREME NETWORKS INC.
DGII DIGI INTERNATIONAL INC.
CIEN COMMSCOPE HOLDING CO. INC.
CASY CIENA CORPORATION
APH CASEY'S GENERAL STORES INC.
SILC AMPHENOL CORPORATION CLASS A
AAOI SILICOM LTD.
BELFB APPLIED OPTOELECTRONICS INC.
CAAP BEL FUSE INC. CL B
COMM CORPORACION AMERICA AIRPORTS
NTGR BMO GLOBAL COMMUNICATIONS INDEX ETF
NETANEL GROUP LTD
Dentsply Sirona Declares Quarterly Cash Dividend
Dentsply Sirona Declares Quarterly Cash Dividend CHARLOTTE, N.C., Dec. 13, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on January 10, 2025, to holders of record as of December 27, 2024. About Dentsply Sirona Dentsply Sirona is the world’s largest manufacturer of professional dental products and technologies, with over a century of innovation and servi...
Perrigo Co: 1 director
A director at Perrigo Co sold 17,598 shares at 28.270USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCO...
Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCONx Conference CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the 7th Annual Evercore ISI HealthCONx Conference. Management is scheduled to participate in a fireside chat discussion on December 5, 2024, at 8:20 am ET. Investors and other interested parties will be able to access a live audio webcast and audio webcast replay by visiting the Investors section of the Dentsply Sirona website at ...
Dentsply Sirona Appoints Herman V. Cueto Interim Chief Financial Offic...
Dentsply Sirona Appoints Herman V. Cueto Interim Chief Financial Officer CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that Herman V. Cueto, a seasoned healthcare executive, has been appointed Interim Chief Financial Officer, effective immediately. He brings over two decades of experience leading and working in finance organizations across the healthcare industry. Mr. Cueto will oversee the finance organization while Dentsply Sirona completes its ongoing search for the Company’s next CFO. “We ar...
Iterum Therapeutics Regains Full Nasdaq Compliance
Iterum Therapeutics Regains Full Nasdaq Compliance Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has bee...
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
Iterum Therapeutics Reports Third Quarter 2024 Financial Results -- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024. “With last month’s approval of ORLYNVAHTM, we have r...
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on ...
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Thursday, November 14, 2024. Management will host a conference call at 8:30 a.m. ET that day ...
Dentsply Sirona Reports Third Quarter 2024 Results
Dentsply Sirona Reports Third Quarter 2024 Results Net sales of $951 million increased 0.5%, organic sales increased 1.3%GAAP gross margin of 52.1%, GAAP net loss of ($494) million or loss per share of ($2.46)Adjusted EBITDA margin of 17.9%, adjusted EPS of $0.50Revised FY24 outlook: expect organic sales of (3.5%) to (2.5%) (previously (1%) to flat); adjusted EPS of $1.82 to $1.86 (previously $1.96 to $2.02) CHARLOTTE, N.C., Nov. 07, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced its financial results for th...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
LINC LINCOLN EDUCATIONAL SERVICES
COMM COMMSCOPE HOLDING CO. INC.
EVR EVERCORE INC CLASS A
CW CURTISS-WRIGHT CORPORATION
HRI HERC HOLDINGS INC.
LBRDA LIBERTY BROADBAND CORP. CLASS A
UNFI UNITED NATURAL FOODS INC.
PAR PAR TECHNOLOGY CORP.
BKNG BOOKING HOLDINGS INC.
UPWK UPWORK
PAY PAYMENTUS HLDGS INC
2VZ LEONARDO DRS INC.
PJT MERRILL LYNCH DEPOSIT GEC-1 A 6.05%
GLXG GALAXY PAYROLL GROUP LTD
FWONK LIBERTY FORMULA ONE
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulo...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), today announced that the U.S. Food and Drug Administration (FDA) has approved Iterum’s new drug application for ORLYNVAH™ (sulopenem...
Dentsply Sirona to Host Conference Call Regarding Update on Byte Align...
Dentsply Sirona to Host Conference Call Regarding Update on Byte Aligner Products CHARLOTTE, N.C., Oct. 25, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced it will host a conference call to discuss its Byte Aligner business. Dentsply Sirona’s management team will host an investor conference call and live webcast on October 25, 2024, at 9:00 am ET. For those planning to participate on the call, please register at . A webcast replay of the conference call will be available on the Investors section of the Company’s website ...
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Iterum Therapeutics to Present Data at IDWeek 2024
Iterum Therapeutics to Present Data at IDWeek 2024 DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at the Infectious Disease Society of America’s IDWeek 2024 conference taking place in Los Angeles, CA from October 16-19, 2024. Data to be presented at IDWeek 2024 include: Pres...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtua...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to treat infections caused by multi-drug resistant pathogens in community settings, today announced it will participate in the 2024 Maxim Healthcare Virtual Summit. Corey Fishman, CEO of Iterum, will join Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group, for a Fireside...
Dentsply Sirona to Host Third Quarter Conference Call on November 7th
Dentsply Sirona to Host Third Quarter Conference Call on November 7th CHARLOTTE, N.C., Oct. 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, November 7, 2024, at 8:30 am ET to review its third quarter financial results. A presentation related to the call will be available on the Investors section of the Company’s website at . Conference Call / Webcast Information A live webcast will be available on the Investors section of the Co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.